| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | Xiao Yu | |
| Shuliang Chen | |||
| Deyin Guo | |||
| P2860 | cites work | Geminivirus disease complexes: the threat is spreading. | Q51225581 |
| C2c1-sgRNA Complex Structure Reveals RNA-Guided DNA Cleavage Mechanism. | Q51252507 | ||
| Generation of knockout mice by Cpf1-mediated gene targeting. | Q51715364 | ||
| HIV: Shock and kill. | Q55056512 | ||
| Guidelines for Confidentiality in Research on AIDS | Q72416943 | ||
| Genome-scale RNAi screen for host factors required for HIV replication | Q79769455 | ||
| Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus | Q21128797 | ||
| Hepatitis B virus X protein upregulates HSP90alpha expression via activation of c-Myc in human hepatocarcinoma cell line, HepG2 | Q21245106 | ||
| Discovery and Functional Characterization of Diverse Class 2 CRISPR-Cas Systems | Q21508512 | ||
| HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor | Q22242268 | ||
| Identification of a major co-receptor for primary isolates of HIV-1 | Q22251282 | ||
| Newly identified host factors modulate HIV replication | Q22252434 | ||
| HIV-1 capsid-cyclophilin interactions determine nuclear import pathway, integration targeting and replication efficiency | Q24300016 | ||
| T-cell immunoglobulin and mucin domain 1 (TIM-1) is a receptor for Zaire Ebolavirus and Lake Victoria Marburgvirus | Q24301153 | ||
| LEDGF/p75 is essential for nuclear and chromosomal targeting of HIV-1 integrase in human cells | Q24304259 | ||
| Identification of host proteins required for HIV infection through a functional genomic screen | Q24306298 | ||
| Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC | Q24329089 | ||
| Small molecule inhibitors reveal Niemann-Pick C1 is essential for Ebola virus infection | Q24329155 | ||
| Ebola virus entry requires the cholesterol transporter Niemann-Pick C1 | Q24329246 | ||
| Human MX2 is an interferon-induced post-entry inhibitor of HIV-1 infection | Q24336824 | ||
| Distinct patterns of IFITM-mediated restriction of filoviruses, SARS coronavirus, and influenza A virus | Q24337838 | ||
| Excision of HIV-1 DNA by gene editing: a proof-of-concept in vivo study | Q40668686 | ||
| Lentivirus pre-packed with Cas9 protein for safer gene editing | Q40725476 | ||
| CRISPR/Cas9 produces anti-hepatitis B virus effect in hepatoma cells and transgenic mouse | Q40726923 | ||
| Inhibition of hepatitis B virus by the CRISPR/Cas9 system via targeting the conserved regions of the viral genome | Q41026337 | ||
| Use of the CRISPR/Cas9 system as an intracellular defense against HIV-1 infection in human cells | Q41265657 | ||
| SAMHD1: a new contributor to HIV-1 restriction in resting CD4+ T-cells. | Q41384553 | ||
| Harnessing the clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated Cas9 system to disrupt the hepatitis B virus | Q41503381 | ||
| Two distinct RNase activities of CRISPR-C2c2 enable guide-RNA processing and RNA detection | Q41558629 | ||
| Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR/Cas RNA-guided DNA endonuclease | Q41566723 | ||
| Establishing a CRISPR-Cas-like immune system conferring DNA virus resistance in plants. | Q41573592 | ||
| CRISPR/Cas9-mediated genome editing of Epstein-Barr virus in human cells. | Q41601689 | ||
| Ebola Virus Binding to Tim-1 on T Lymphocytes Induces a Cytokine Storm. | Q41676229 | ||
| Cells nonproductively infected with HIV-1 exhibit an aberrant pattern of viral RNA expression: a molecular model for latency | Q41730261 | ||
| Phase 2 Placebo-Controlled Trial of Two Vaccines to Prevent Ebola in Liberia | Q41918936 | ||
| Chaperone activation of the hepadnaviral reverse transcriptase for template RNA binding is established by the Hsp70 and stimulated by the Hsp90 system | Q41933522 | ||
| Expanding CRISPR/Cas9 Genome Editing Capacity in Zebrafish Using SaCas9. | Q42130461 | ||
| Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26. | Q42152380 | ||
| Study of accuracy of colposcopy in VIA and HPV detection-based cervical cancer screening program | Q42177590 | ||
| Establishment of three new genera in the family Geminiviridae: Becurtovirus, Eragrovirus and Turncurtovirus | Q42229655 | ||
| In vitro activity of cepharanthine hydrochloride against clinical wild-type and lamivudine-resistant hepatitis B virus isolates | Q42720808 | ||
| Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women | Q43655015 | ||
| Ebola virus disease: an update on post-exposure prophylaxis | Q44106299 | ||
| Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. | Q45396940 | ||
| Human immunodeficiency virus type 1 restriction by human-rhesus chimeric tripartite motif 5alpha (TRIM 5alpha) in CD34(+) cell-derived macrophages in vitro and in T cells in vivo in severe combined immunodeficient (SCID-hu) mice transplanted with hu | Q45397087 | ||
| Gamma-adaptin, a novel ubiquitin-interacting adaptor, and Nedd4 ubiquitin ligase control hepatitis B virus maturation | Q45414100 | ||
| Genome modification of CXCR4 by Staphylococcus aureus Cas9 renders cells resistance to HIV-1 infection | Q45874506 | ||
| Targeting TRIM5α in HIV Cure Strategies for the CRISPR-Cas9 Era. | Q45875539 | ||
| RNA targeting with CRISPR-Cas13. | Q46092009 | ||
| RNA editing with CRISPR-Cas13. | Q47410076 | ||
| Angiotensin-converting enzyme 2 protects from severe acute lung failure | Q47768368 | ||
| Genome-wide analysis reveals specificities of Cpf1 endonucleases in human cells | Q48210394 | ||
| Seamless modification of wild-type induced pluripotent stem cells to the natural CCR5Δ32 mutation confers resistance to HIV infection | Q33854184 | ||
| A genome-wide CRISPR screen identifies a restricted set of HIV host dependency factors. | Q33906477 | ||
| Generation of marker-free transgenic plants concurrently resistant to a DNA geminivirus and a RNA tospovirus | Q33912700 | ||
| RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection. | Q34025414 | ||
| Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex | Q34042665 | ||
| In vivo genome editing using Staphylococcus aureus Cas9 | Q34043628 | ||
| Cas9-mediated targeting of viral RNA in eukaryotic cells | Q34043858 | ||
| MX2 is an interferon-induced inhibitor of HIV-1 infection | Q24338311 | ||
| SERINC3 and SERINC5 restrict HIV-1 infectivity and are counteracted by Nef | Q24338889 | ||
| HIV-1 Nef promotes infection by excluding SERINC5 from virion incorporation | Q24338895 | ||
| Hepatitis B virus large envelope protein interacts with gamma2-adaptin, a clathrin adaptor-related protein | Q24529521 | ||
| A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion | Q24568052 | ||
| RNA-guided human genome engineering via Cas9 | Q24598394 | ||
| SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx | Q24605940 | ||
| Multiplex genome engineering using CRISPR/Cas systems | Q24609428 | ||
| SAMHD1 restricts HIV-1 reverse transcription in quiescent CD4(+) T-cells | Q24615124 | ||
| SAMHD1 restricts the replication of human immunodeficiency virus type 1 by depleting the intracellular pool of deoxynucleoside triphosphates | Q24624362 | ||
| CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes | Q24625361 | ||
| Ebola virus entry requires the host-programmed recognition of an intracellular receptor | Q24629282 | ||
| Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein | Q24635842 | ||
| Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system | Q24669821 | ||
| A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity | Q24669850 | ||
| Genetic dissection of Flaviviridae host factors through genome-scale CRISPR screens | Q24705236 | ||
| A CRISPR screen defines a signal peptide processing pathway required by flaviviruses | Q24705237 | ||
| Identification of Zika Virus and Dengue Virus Dependency Factors using Functional Genomics | Q24706780 | ||
| Methods and clinical development of adenovirus-vectored vaccines against mucosal pathogens | Q26750912 | ||
| Application of CRISPR/Cas9 Technology to HBV | Q26779150 | ||
| CCR5 Targeted Cell Therapy for HIV and Prevention of Viral Escape | Q26801498 | ||
| The LEDGF/p75 integrase interaction, a novel target for anti-HIV therapy | Q26849265 | ||
| HIV-1 eradication strategies: design and assessment | Q26864933 | ||
| Adenovirus vectors for gene therapy, vaccination and cancer gene therapy | Q27001601 | ||
| Epstein-barr virus sequence variation-biology and disease | Q27003183 | ||
| Novel mechanisms of EBV-induced oncogenesis | Q27006524 | ||
| CRISPR-Cas systems: Prokaryotes upgrade to adaptive immunity | Q27014828 | ||
| HIV-HCV co-infection: epidemiology, pathogenesis and therapeutic implications | Q27026182 | ||
| Functional screen reveals SARS coronavirus nonstructural protein nsp14 as a novel cap N7 methyltransferase | Q27487986 | ||
| CPSF6 Defines a Conserved Capsid Interface that Modulates HIV-1 Replication | Q27672646 | ||
| Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4 | Q27678981 | ||
| Crystal Structure of Cas9 in Complex with Guide RNA and Target DNA | Q27681727 | ||
| CRISPR/Cas9-mediated viral interference in plants | Q34045362 | ||
| Inactivation of the human papillomavirus E6 or E7 gene in cervical carcinoma cells by using a bacterial CRISPR/Cas RNA-guided endonuclease. | Q34261483 | ||
| Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy | Q34290545 | ||
| The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus. | Q34318146 | ||
| The spatio-temporal distribution dynamics of Ebola virus proteins and RNA in infected cells | Q34326340 | ||
| A CRISPR/Cas system mediates bacterial innate immune evasion and virulence | Q34339102 | ||
| Involvement of the host DNA-repair enzyme TDP2 in formation of the covalently closed circular DNA persistence reservoir of hepatitis B viruses | Q34407460 | ||
| The CRISPR/Cas9 System Facilitates Clearance of the Intrahepatic HBV Templates In Vivo | Q34459390 | ||
| CRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus | Q34478938 | ||
| A CRISPR-Based Screen Identifies Genes Essential for West-Nile-Virus-Induced Cell Death | Q34485801 | ||
| Inhibition of HSV-1 Replication by Gene Editing Strategy | Q34521509 | ||
| The CRISPR-associated DNA-cleaving enzyme Cpf1 also processes precursor CRISPR RNA. | Q34522844 | ||
| C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector | Q34529451 | ||
| RNA-guided endonuclease provides a therapeutic strategy to cure latent herpesviridae infection | Q34583415 | ||
| Towards an HIV cure: a global scientific strategy | Q34640562 | ||
| Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus | Q34655645 | ||
| Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter, sodium taurocholate cotransporting polypeptide (NTCP). | Q34693445 | ||
| Removal of arginine 332 allows human TRIM5alpha to bind human immunodeficiency virus capsids and to restrict infection | Q34717834 | ||
| Efficient ablation of genes in human hematopoietic stem and effector cells using CRISPR/Cas9 | Q34727851 | ||
| Targeting Hepatitis B Virus With CRISPR/Cas9. | Q34745348 | ||
| EBV-driven B-cell lymphoproliferative disorders: from biology, classification and differential diagnosis to clinical management | Q35040644 | ||
| High-throughput screening of a CRISPR/Cas9 library for functional genomics in human cells | Q35143589 | ||
| A Dual-reporter system for real-time monitoring and high-throughput CRISPR/Cas9 library screening of the hepatitis C virus | Q35157137 | ||
| High-efficiency targeted editing of large viral genomes by RNA-guided nucleases | Q35161635 | ||
| The CRISPR/Cas9 system inactivates latent HIV-1 proviral DNA | Q35177829 | ||
| Human papillomaviruses: targeting differentiating epithelial cells for malignant transformation | Q35196630 | ||
| Does Tyrosyl DNA Phosphodiesterase-2 Play a Role in Hepatitis B Virus Genome Repair? | Q35664939 | ||
| Identification of BST-2/tetherin-induced hepatitis B virus restriction and hepatocyte-specific BST-2 inactivation | Q35792954 | ||
| The Interferon-Inducible Protein Tetherin Inhibits Hepatitis B Virus Virion Secretion | Q35973592 | ||
| Dual gRNAs guided CRISPR/Cas9 system inhibits hepatitis B virus replication | Q35992385 | ||
| Crystal Structure of Cpf1 in Complex with Guide RNA and Target DNA | Q35999041 | ||
| Post-Transcriptional Regulation of KLF4 by High-Risk Human Papillomaviruses Is Necessary for the Differentiation-Dependent Viral Life Cycle. | Q36069580 | ||
| The Replicative Consequences of Papillomavirus E2 Protein Binding to the Origin Replication Factor ORC2 | Q36152782 | ||
| Genome editing of CXCR4 by CRISPR/cas9 confers cells resistant to HIV-1 infection. | Q36181852 | ||
| STRUCTURAL BIOLOGY. A Cas9-guide RNA complex preorganized for target DNA recognition | Q27701410 | ||
| Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein | Q27860488 | ||
| Replication of hepatitis C virus | Q27860957 | ||
| Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA | Q27861124 | ||
| Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus | Q28188496 | ||
| Characterization of a novel coronavirus associated with severe acute respiratory syndrome | Q28202401 | ||
| Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV | Q28235281 | ||
| Development and applications of CRISPR-Cas9 for genome engineering | Q28241526 | ||
| A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury | Q28260798 | ||
| HIV entry and its inhibition | Q28273919 | ||
| Update on acquired immune deficiency syndrome (AIDS)--United States | Q28274386 | ||
| Small CRISPR RNAs guide antiviral defense in prokaryotes | Q28290898 | ||
| RNA-guided gene activation by CRISPR-Cas9-based transcription factors | Q28295458 | ||
| The CRISPR/Cas bacterial immune system cleaves bacteriophage and plasmid DNA | Q28297640 | ||
| Evidence for the cure of HIV infection by CCR5Δ32/Δ32 stem cell transplantation | Q28300338 | ||
| CCR5 gene disruption via lentiviral vectors expressing Cas9 and single guided RNA renders cells resistant to HIV-1 infection | Q28542878 | ||
| CRISPR/Cas9-Mediated Genome Editing of Herpesviruses Limits Productive and Latent Infections | Q28552274 | ||
| Nucleic acid detection with CRISPR-Cas13a/C2c2 | Q29385392 | ||
| Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators | Q29547281 | ||
| The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys | Q29547689 | ||
| Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu | Q29547836 | ||
| Papillomaviruses and cancer: from basic studies to clinical application | Q29614745 | ||
| Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation | Q29615068 | ||
| Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression | Q29615784 | ||
| Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy | Q29615992 | ||
| Genome-scale CRISPR-Cas9 knockout screening in human cells | Q29616044 | ||
| Global analysis of host-pathogen interactions that regulate early-stage HIV-1 replication | Q29616375 | ||
| CRISPR RNA-guided activation of endogenous human genes | Q29617072 | ||
| Genetic screens in human cells using the CRISPR-Cas9 system | Q29617411 | ||
| The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein | Q29619540 | ||
| Diagnosis, management, and treatment of hepatitis C | Q29620656 | ||
| A CRISPR toolbox to study virus-host interactions | Q29994612 | ||
| SAMHD1 restricts HIV-1 infection in resting CD4(+) T cells. | Q30421200 | ||
| A protein-tagging system for signal amplification in gene expression and fluorescence imaging | Q30604320 | ||
| Mutation of a single residue renders human tetherin resistant to HIV-1 Vpu-mediated depletion | Q33450556 | ||
| Generation of human TRIM5alpha mutants with high HIV-1 restriction activity | Q33548284 | ||
| Characterization of human immunodeficiency virus type 1 populations containing CXCR4-using variants from recently infected individuals | Q33685141 | ||
| Efficient inhibition of hepatitis B virus infection by acylated peptides derived from the large viral surface protein | Q33717942 | ||
| Heat stress cognate 70 host protein as a potential drug target against drug resistance in hepatitis B virus | Q33826248 | ||
| CRISPR/Cas9-The ultimate weapon to battle infectious diseases? | Q36196813 | ||
| The CXCL12/CXCR4 Signaling Pathway: A New Susceptibility Factor in Human Papillomavirus Pathogenesis | Q36213484 | ||
| CRISPR/gRNA-directed synergistic activation mediator (SAM) induces specific, persistent and robust reactivation of the HIV-1 latent reservoirs | Q36250079 | ||
| Crystal Structure of Staphylococcus aureus Cas9 | Q36348284 | ||
| Molecular dissection of HBV evasion from restriction factor tetherin: A new perspective for antiviral cell therapy | Q36355811 | ||
| Change in coreceptor use correlates with disease progression in HIV-1--infected individuals | Q36376800 | ||
| Specific induction of endogenous viral restriction factors using CRISPR/Cas-derived transcriptional activators | Q36435381 | ||
| CRISPR-mediated Activation of Latent HIV-1 Expression | Q36675297 | ||
| Specific Reactivation of Latent HIV-1 by dCas9-SunTag-VP64-mediated Guide RNA Targeting the HIV-1 Promoter | Q36675349 | ||
| Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template | Q36684377 | ||
| Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. | Q36828138 | ||
| Temporal aspects of DNA and RNA synthesis during human immunodeficiency virus infection: evidence for differential gene expression | Q36830303 | ||
| Highly specific targeted mutagenesis in plants using Staphylococcus aureus Cas9 | Q36937761 | ||
| The clinical applications of genome editing in HIV. | Q36942032 | ||
| Immune responses to AAV vectors: overcoming barriers to successful gene therapy | Q36983740 | ||
| A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif). | Q37095343 | ||
| Immunity to adeno-associated virus vectors in animals and humans: a continued challenge | Q37127246 | ||
| Efficient Production of Gene-Modified Mice using Staphylococcus aureus Cas9. | Q37227736 | ||
| Potent inhibition of HIV-1 by TRIM5-cyclophilin fusion proteins engineered from human components | Q37363070 | ||
| The challenge of finding a cure for HIV infection | Q37407598 | ||
| Brd4 Activates Early Viral Transcription upon Human Papillomavirus 18 Infection of Primary Keratinocytes | Q37430517 | ||
| A Cas9 Ribonucleoprotein Platform for Functional Genetic Studies of HIV-Host Interactions in Primary Human T Cells | Q37441674 | ||
| Efficient targeted mutagenesis of rice and tobacco genomes using Cpf1 from Francisella novicida | Q37460202 | ||
| Multiplex gene editing by CRISPR-Cpf1 using a single crRNA array | Q37578175 | ||
| Removal of Integrated Hepatitis B Virus DNA Using CRISPR-Cas9. | Q37714431 | ||
| Hsp90 is required for the activity of a hepatitis B virus reverse transcriptase | Q37729269 | ||
| Human papillomavirus oncoproteins: pathways to transformation | Q37769103 | ||
| Oxidative stress and mitochondrial impairment after treatment with anti-HIV drugs: clinical implications | Q37970464 | ||
| Developing strategies for HIV-1 eradication | Q38032363 | ||
| Geminiviruses: masters at redirecting and reprogramming plant processes | Q38150077 | ||
| Dynamic Epstein-Barr virus gene expression on the path to B-cell transformation | Q38174306 | ||
| The immunology of Epstein-Barr virus-induced disease | Q38364278 | ||
| Delivery and Specificity of CRISPR-Cas9 Genome Editing Technologies for Human Gene Therapy. | Q38525774 | ||
| Highly efficient homology-driven genome editing in human T cells by combining zinc-finger nuclease mRNA and AAV6 donor delivery. | Q38530599 | ||
| CRISPR/Cas9-based tools for targeted genome editing and replication control of HBV. | Q38618922 | ||
| Complete Spectrum of CRISPR/Cas9-induced Mutations on HBV cccDNA. | Q38769680 | ||
| Two Distant Catalytic Sites Are Responsible for C2c2 RNase Activities | Q38770695 | ||
| Potent and Targeted Activation of Latent HIV-1 Using the CRISPR/dCas9 Activator Complex | Q38818673 | ||
| Inhibition of HIV-1 infection of primary CD4+ T-cells by gene editing of CCR5 using adenovirus-delivered CRISPR/Cas9. | Q38889625 | ||
| Targeting hepatitis B virus cccDNA by CRISPR/Cas9 nuclease efficiently inhibits viral replication. | Q38890817 | ||
| A CRISPR-Cpf1 system for efficient genome editing and transcriptional repression in plants. | Q38955410 | ||
| In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by CRISPR/Cas9. | Q38973597 | ||
| TALEN knockout of the PSIP1 gene in human cells: analyses of HIV-1 replication and allosteric integrase inhibitor mechanism | Q38983286 | ||
| Host cell restriction factors that limit transcription and replication of human papillomavirus. | Q39013547 | ||
| Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor | Q39051196 | ||
| Generation of an HIV resistant T-cell line by targeted "stacking" of restriction factors | Q39203103 | ||
| CRISPR/Cas9: at the cutting edge of hepatology. | Q39294371 | ||
| A decade of discovery: CRISPR functions and applications | Q39350951 | ||
| Cpf1 Is A Versatile Tool for CRISPR Genome Editing Across Diverse Species of Cyanobacteria | Q39613576 | ||
| Simultaneous Knockout of CXCR4 and CCR5 Genes in CD4+ T Cells via CRISPR/Cas9 Confers Resistance to Both X4- and R5-Tropic Human Immunodeficiency Virus Type 1 Infection | Q39619539 | ||
| Heat shock protein 90 facilitates formation of the HBV capsid via interacting with the HBV core protein dimers. | Q39624638 | ||
| Genome editing of the HIV co-receptors CCR5 and CXCR4 by CRISPR-Cas9 protects CD4+ T cells from HIV-1 infection | Q40042102 | ||
| The gRNA-miRNA-gRNA Ternary Cassette Combining CRISPR/Cas9 with RNAi Approach Strongly Inhibits Hepatitis B Virus Replication | Q40070996 | ||
| A CRISPR Activation Screen Identifies a Pan-avian Influenza Virus Inhibitory Host Factor | Q40081243 | ||
| The tetraspanin CD9 facilitates MERS-coronavirus entry by scaffolding host cell receptors and proteases. | Q40101206 | ||
| CRISPR/Cas9-Mediated CCR5 Ablation in Human Hematopoietic Stem/Progenitor Cells Confers HIV-1 Resistance In Vivo | Q40192805 | ||
| CRISPR/Cas9 Screens Reveal Epstein-Barr Virus-Transformed B Cell Host Dependency Factors | Q40205659 | ||
| In Vivo Excision of HIV-1 Provirus by saCas9 and Multiplex Single-Guide RNAs in Animal Models | Q40263108 | ||
| Hepatitis B Virus-Infected HepG2hNTCP Cells Serve as a Novel Immunological Tool To Analyze the Antiviral Efficacy of CD8+ T Cells In Vitro | Q40280446 | ||
| The Deacetylase SIRT1 Regulates the Replication Properties of Human Papillomavirus 16 E1 and E2. | Q40301195 | ||
| A non-viral CRISPR/Cas9 delivery system for therapeutically targeting HBV DNA and pcsk9 in vivo. | Q40360360 | ||
| PAM-Dependent Target DNA Recognition and Cleavage by C2c1 CRISPR-Cas Endonuclease | Q40406605 | ||
| Down-regulation of microRNA-146a is associated with high-risk human papillomavirus infection and epidermal growth factor receptor overexpression in penile squamous cell carcinoma. | Q40462022 | ||
| KLF13 regulates the differentiation-dependent human papillomavirus life cycle in keratinocytes through STAT5 and IL-8. | Q40500885 | ||
| CRISPR/Cas9 nickase-mediated disruption of hepatitis B virus open reading frame S and X. | Q40580426 | ||
| CRISPR/Cas9-Mediated Immunity to Geminiviruses: Differential Interference and Evasion. | Q40659541 | ||
| P275 | copyright license | Creative Commons Attribution | Q6905323 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P921 | main subject | regulation of gene expression | Q411391 |
| CRISPR | Q412563 | ||
| viral infectious disease | Q1928978 | ||
| gene editing | Q65363531 | ||
| biomedical investigative technique | Q66648976 | ||
| host microbial interaction | Q68260314 | ||
| CRISPR-Cas systems | Q71149179 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 40 | |
| P577 | publication date | 2018-01-16 | |
| P1433 | published in | Viruses | Q7935305 |
| P1476 | title | CRISPR-Cas Targeting of Host Genes as an Antiviral Strategy | |
| P478 | volume | 10 |
| Q64060697 | Application of CRISPR/Cas9-Based Gene Editing in HIV-1/AIDS Therapy |
| Q91970445 | Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects |
| Q64923390 | CCR5 editing by Staphylococcus aureus Cas9 in human primary CD4+ T cells and hematopoietic stem/progenitor cells promotes HIV-1 resistance and CD4+ T cell enrichment in humanized mice. |
| Q55333943 | Cell Line Techniques and Gene Editing Tools for Antibody Production: A Review. |
| Q52431359 | Genome scale screening identification of SaCas9/gRNAs for targeting HIV-1 provirus and suppression of HIV-1 infection. |
| Q55190209 | HIV-1 inhibition in cells with CXCR4 mutant genome created by CRISPR-Cas9 and piggyBac recombinant technologies. |
| Q90061988 | Special Issue: Applications of CRISPR Technology in Virology 2018 |
| Q92814609 | The Revival of the Battle between David and Goliath in the Enteric Viruses and Microbiota Struggle: Potential Implication for Celiac Disease |
Search more.